ValiRx (LSE:VAL) Accounts Payable & Accrued Expense

: £0.09 Mil (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

ValiRx's quarterly accounts payable & accrued expense declined from Jun. 2022 (£0.28 Mil) to Dec. 2022 (£0.05 Mil) but then increased from Dec. 2022 (£0.05 Mil) to Jun. 2023 (£0.09 Mil).

ValiRx's annual accounts payable & accrued expense declined from Dec. 2020 (£0.08 Mil) to Dec. 2021 (£0.02 Mil) but then increased from Dec. 2021 (£0.02 Mil) to Dec. 2022 (£0.05 Mil).

ValiRx Accounts Payable & Accrued Expense Historical Data

The historical data trend for ValiRx's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable & Accrued Expense

0.84

1.09

0.08

0.02

0.05

ValiRx Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Accounts Payable & Accrued Expense																0.06	0.02	0.28	0.05	0.09

ValiRx Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

ValiRx (LSE:VAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

EAJF:Germany

Address

4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH

Website

https://www.valirx.com

ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.